What PDRN is, and why its length matters

PDRN is a mixture of short DNA fragments. Its chemistry is simple to state and hard to control, and the control is where a medicine begins.

PDRN stands for polydeoxyribonucleotide. It is a mixture of short pieces of DNA, each a chain of the same four building blocks that every cell uses: adenine, guanine, cytosine and thymine, joined on a backbone of sugar and phosphate. There is nothing exotic in the material. What makes it a candidate for medicine is not what it is made of but the size of the pieces.

A gene runs to thousands of base pairs. The fragments in PDRN are far shorter. The PDRN described in the scientific literature spans a wide range, roughly 50 to 2,000 base pairs, and much of it comes from a single animal source. The width of that range is the problem we set out to solve. A fragment of 50 base pairs and a fragment of 1,500 base pairs are different molecules to a cell: they diffuse differently, they bind differently, and they are broken down at different rates.

Why one length

Our target is a narrow window, about 20 to 80 base pairs. Holding a mixture inside that window does two things. It makes every batch comparable with the last, which is the foundation of any pharmaceutical process. And it lets us ask a precise question of the biology: what does a fragment of this size do, and through which receptors?

The published research points to several routes. The best supported is the adenosine A2A receptor on the surface of cells, described in reviews such as Squadrito and colleagues (Frontiers in Pharmacology, 2017). Others are proposed: the TLR9 receptor, which recognises certain DNA motifs (Hemmi and colleagues, Nature, 2000), the DNA sensors inside the cell, and the salvage pathway, in which a cell takes up nucleotides and reuses them for its own DNA. Which of these matter for a fragment of a given length is a question we can only answer if the length is known.

What this is not

None of this is a claim about what PDRN does in people. Our programmes are in research and preclinical work, and nothing on this site establishes the safety or efficacy of any Synthena medicine. It is a description of a material, and of why we insist on measuring it before we say anything else.

References: Squadrito F. et al., Pharmacological activity and clinical use of PDRN, Frontiers in Pharmacology, 2017. Hemmi H. et al., A Toll-like receptor recognizes bacterial DNA, Nature, 2000.

The views in a post are the author's. Nothing here establishes the safety or efficacy of any Synthena medicine; our programmes are in research and preclinical development.

All insights